-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Individual Investors Among Shanghai Bio-heart Biological Technology Co., Ltd.'s (HKG:2185) Largest Stockholders and Were Hit After Last Week's 6.9% Price Drop
Individual Investors Among Shanghai Bio-heart Biological Technology Co., Ltd.'s (HKG:2185) Largest Stockholders and Were Hit After Last Week's 6.9% Price Drop
A look at the shareholders of Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 50% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
And following last week's 6.9% decline in share price, individual investors suffered the most losses.
Let's delve deeper into each type of owner of Shanghai Bio-heart Biological Technology, beginning with the chart below.
See our latest analysis for Shanghai Bio-heart Biological Technology
SEHK:2185 Ownership Breakdown October 25th 2022What Does The Institutional Ownership Tell Us About Shanghai Bio-heart Biological Technology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Shanghai Bio-heart Biological Technology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shanghai Bio-heart Biological Technology's earnings history below. Of course, the future is what really matters.
SEHK:2185 Earnings and Revenue Growth October 25th 2022We note that hedge funds don't have a meaningful investment in Shanghai Bio-heart Biological Technology. Shanghai Baixinantong Enterprise Management Consulting L.P is currently the company's largest shareholder with 11% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 10% and 8.5%, of the shares outstanding, respectively.
On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
Insider Ownership Of Shanghai Bio-heart Biological Technology
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our data cannot confirm that board members are holding shares personally. It is rare to see such a low level of personal ownership, amongst the board (and it is possible that our data might be incomplete). Concerned investors should check here to see if insiders have been selling or buying.
General Public Ownership
With a 50% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shanghai Bio-heart Biological Technology. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Equity Ownership
With an ownership of 8.5%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
Private Company Ownership
Our data indicates that Private Companies hold 20%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Shanghai Bio-heart Biological Technology that you should be aware of.
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看上海生物心臟生物科技股份有限公司(HKG:2185)的股東可以告訴我們哪個群體最強大。我們可以看到,個人投資者擁有 50% 所有權的公司中的最大份額。也就是說,如果股票上漲,該集團受益最大(或者如果出現低迷,則損失最多)。
繼上周股價下跌 6.9% 之後,個人投資者蒙受最大損失。
讓我們深入研究上海生物心臟生物技術的每種類型的所有者,從下面的圖表開始。
查看我們有關上海生物心臟生物科技的最新分析
香港聯交所:2185 擁有權分佈 2022 年十月二十五日機構所有權告訴我們關於上海生物心臟生物技術的哪些內容?
機構在向自己的投資者匯報時,通常會根據基準來衡量自己,因此一旦股票被納入主要指數,他們通常會對股票更加熱情。我們希望大多數公司都會在註冊機構中註冊一些機構,特別是如果它們正在增長。
上海生物心臟生物科技有限公司已經擁有股份登記機構。事實上,他們在公司擁有可觀的股份。這可以表明該公司在投資界具有一定程度的信譽。但是,最好警惕依靠機構投資者所提供的驗證。他們也是,有時會弄錯。如果多個機構同時改變了對股票的看法,您可能會看到股價快速下降。因此值得一看下面的上海生物心臟生物科技的收益歷史。當然,未來才是真正重要的。
聯交所代碼:2185 2022 年十月二十五日盈利及收入增長我們注意到,對沖基金對上海生物心臟生物技術沒有有意義的投資。上海百心通企業管理咨詢有限責任公司是目前公司最大的股東,擁有 11% 的已發行股份。與此同時,第二大和第三大股東分別持有 10% 和 8.5% 的已發行股份。
在進一步檢查中,我們發現公司一半以上的股份是由前 10 名股東擁有的,這表明較大股東的利益在一定程度上由較小的股東平衡。
儘管研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向吹來也是有意義的。我們目前沒有拿起該股票的任何分析師報導,因此該公司不太可能被廣泛持有。
上海生物心臟生物科技的內幕擁有權
公司內部人員的定義可以是主觀的,並且在司法管轄區之間確實有所不同。我們的數據反映了個別內部人員,至少捕獲董事會成員。公司管理層運行的業務,但 CEO 會回答董事會,即使他或她是它的成員。
大多數人認為內幕所有權是積極的,因為它可以表明董事會與其他股東保持一致。但是,在某些情況下,這個組中集中了太多的權力。
我們的數據無法確認董事會成員是否親自持有股份。在董事會中很少看到如此低的個人所有權水平(並且可能是我們的數據可能不完整)。有關投資者應在此處查看內部人士是否一直在出售或購買。
一般公共所有權
擁有 50% 的所有權,普通大眾(主要由個人投資者組成)擁有一定程度的上海生物心臟生物技術。如果決定與其他大型股東不同步,這種擁有權規模雖然相當大,可能不足以改變公司政策。
私募股權擁有權
私募股權公司擁有 8.5% 的股權,可以在塑造企業戰略方面發揮作用,重點放在價值創造上。有時候,我們看到私募股權投資從長遠來看,但一般來說,它們的投資期限較短,顧名思義--不要對上市公司投資太多。一段時間後,他們可能會尋求在其他地方出售和重新部署資本。
私人公司所有權
我們的數據顯示,私人公司持有公司 20% 的股份。私人公司可能是關聯方。有時候,內部人員通過在私人公司的控股權,而不是以自己的身份作為個人的身份對上市公司有興趣。雖然很難得出任何廣泛的中風結論,但值得注意的是作為進一步研究的領域。
後續步驟:
我覺得看看誰確切擁有一家公司非常有趣。但是要真正獲得洞察力,我們也需要考慮其他信息。例如,我們已經確定 上海生物心臟生物科技有限公司 1 號警示 你應該知道的。
當然 這可能不是最好的股票買。因此,您可能希望看到我們的 自由 收集有趣的前景擁有良好的財務狀況。
注意:本文中的數字是使用過去 12 個月的數據計算的,這些數據是指截至財務報表日期當月最後一個日期的 12 個月期間。這可能與全年年度報告數字不一致。
對這篇文章有反饋嗎?關注內容? 取得聯繫 直接與我們聯繫。 或者,通過電子郵件發送電子郵件給編輯團隊。
這篇文章由簡單牆聖是一般性質. 我們僅使用公正的方法,根據歷史數據和分析師預測提供評論,我們的文章並不打算作為財務建議。 它並不構成購買或出售任何股票的建議,也不會考慮您的目標或您的財務狀況。我們的目標是為您帶來由基本數據驅動的長期集中分析。請注意,我們的分析可能不會考慮最新的價格敏感公司公告或定性材料。簡易華街在提及的任何股票中都沒有倉位。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧